



CONGRESSO
SOCERGS
2 · 0 · 2 · 3

UNIÃO, ATUALIZAÇÃO E NETWORKING

Simpósio
SGCCV/SOCERGS

INDICAÇÃO DE CIRURGIA DE AORTA BASEADA EM PAINEL GENÉTICO. A MEDICINA DE PRECISÃO NA CIRURGIA CARDIOVASCULAR ESTÁ CHEGANDO?

Renato A. K. Kalil

Professor Titular jubilado de Clínica Cirúrgica da UFCSPA

Membro Titular da Academia Sul-Rio-Grandense de Medicina

Coordenador do Núcleo de Cardiopatias Congênicas do Hospital Moinhos de Vento

Cirurgião Cardiovascular nos Hospitais Moinhos de Vento, Divina Providência e Instituto de Cardiologia



Declaração de Potencial Conflito de Interesse

Nome do Palestrante: Renato A. K. Kalil

Título da Apresentação:

***INDICAÇÃO DE CIRURGIA DE AORTA BASEADA
EM PAINEL GENÉTICO.***

A MEDICINA DE PRECISÃO NA CIRURGIA CARDIOVASCULAR ESTÁ CHEGANDO?

**Não possuo nenhum conflito de interesse
relacionado a esta apresentação**

Thoracic aortic aneurysms

Marfan syndrome

Non-Marfan



Surgical intervention thresholds for aortic root & ascending aorta in patients with...

Sporadic and BAV aneurysms*:


5.5 cm (COR 1)

5.0 cm by experienced surgeons in a Multidisciplinary Aortic Team (COR 2a)

Marfan syndrome#:

5.0 cm (COR 1)

≥4.5 cm in those with an increased risk of aortic dissection when performed by experienced surgeons in a Multidisciplinary Aortic Team (COR 2a)



COR 1 (Is recommended)

COR 2a (Is reasonable)

*Surgical thresholds may be adjusted based on patient genetics, rapid aortic growth rate, cross-sectional aortic area/height ratio $\geq 10 \text{ cm}^2/\text{m}$, aortic size index of $\geq 3.08 \text{ cm}/\text{m}^2$, or aortic height index of $\geq 3.21 \text{ cm}/\text{m}$.

#For more on rapid aortic growth rate and patients with nonsyndromic heritable thoracic aortic aneurysms or with genetic aortopathies other than Marfan syndrome (e.g., Loeys-Dietz syndrome), please see the 2022 ACC/AHA Guideline for the Diagnosis & Management of Aortic Disease.

Key Question


What is the natural history of ascending thoracic aortic aneurysm (ATAA), in the absence of pre-emptive surgical intervention?

Key Finding

- ATAAAs enlarged slowly, with growth rates rarely over 0.2 cm/year.
- The risk of adverse aortic events in the ascending thoracic aorta rose sharply at a hinge point of 5 cm.


Take Home Message

- In ATAA patients, prophylactic surgical intervention should be considered at 5 cm.
- Bona fide rapid aortic growth is a valid but unusual criterion for intervention.




To assess the natural history of ascending aortic aneurysm, we examined the three-decade clinical outcomes of 964 non-operated patients with ascending aortic aneurysm. Note, in the 2D plot, the sharp rise in risk of adverse aortic events is at an aortic size of 5 cm. The 3D plot of risk vs. both size and age also discloses a substantial contribution of advancing age to increased risk. ATAA, ascending thoracic aortic aneurysm; AAE, adverse aortic events.

TÉCNICAS CONVENCIONAIS PARA ANEURISMAS DE AORTA ASCENDENTE




BENTALL-DeBONO



DAVID e YACOUB

Valve-sparing aortic root surgery



Buratto & Konstantinov

JTCVS [Congenital: Aorta: Invited Expert Technical Review] [Volume 162](#),
[ISSUE 3](#), P955-962, September 01, 2021

Surgical Treatment of Annuloaortic Ectasia with Composite Grafts Including Homologous Dura Mater Valves

Renato K. Kalil, M.D., Paulo C. Azambuja, M.D., Victor E. Bertolotti, M.D.,
Fernando A. Lucchese, M.D., Paulo R. Prates, M.D., and Ivo A. Nesralla, M.D.

N=3pts, 1976 - 1977






Fig 2. (Patient 3.) Postoperative aortogram. The tube graft is in the ascending aorta, both coronary arteries are well seen, and the aortic valve prosthesis is competent.



Tratamento cirúrgico para ectasia ânulo-aórtica

Ricardo GARCÍA-MACEDO*, Renato A. K. KALIL*, Paulo Roberto PRATES*, Fernando A. LUCCHESI, João Ricardo SANT'ANA*, Edemar M. PEREIRA*, Altamiro Reis COSTA*, Raul Feck A. LARA, Ivo A. NESRALLA*, *Porto Alegre, RS.*

RBCCV

GARCÍA-MACEDO, R.; KALIL, R. A. K.; PRATES, P.R.; LUCCHESI, F.A.; SANT'ANA, J.R.; PEREIRA, E. M.; COSTA, A.R.; LARA, R. F. A.; NESRALLA, I. A. — Tratamento cirúrgico para ectasia ânulo-aórtica. *Rev. Bras. Cir. Cardiovasc.*, 1 (1): 44-48, 1986.

RESUMO: Foram estudados 27 pacientes submetidos a implante de tubo de Dacron valvulado (segundo técnica de Bentall-De Bono), entre 1976 e 1985. Todos apresentavam ectasia ânulo-aórtica, que era devida a necrose cística da média em 23 pacientes (85,2%), dissecação crônica de aorta em 3 pacientes (11,1%) e aortite luética em 1 paciente (3,7%). A faixa etária foi de 29 a 64 anos (m = 48 anos). Três eram do sexo feminino e 24, do masculino. Foi utilizado tubo de Dacron 28 ou 30 mm em todos. As válvulas utilizadas foram: de dura-máter em 7 pacientes, de aorta heteróloga em 9 e metálica em 11 pacientes. A classe funcional era I-II em 7 pacientes e III-IV em 19 pacientes (NYHA). Houve 1 óbito (3,7%) pós-operatório imediato, por sangramento incontrolável e insuficiência renal aguda. As complicações mais frequentes foram

Marfan Syndrome: *FBN1* Pathogenic Variants



Skeletal

Pectus deformities

Tall stature

Scoliosis



Ocular

Ectopia Lentis

Aortic root aneurysms

Surgical repair at 5.0 cm

Low risk for ICAs and peripheral aneurysms

Heritable Thoracic Aortic Disease Genes

ECM

<i>FBN1</i>	fibrillin-1
<i>MFAP5</i>	microfibril associated protein 2
<i>LOX</i>	lysyl oxidase
<i>BGN</i>	biglycan
<i>LTBP3</i>	latent TGF- β binding protein

TGF- β Signaling

<i>TGFBR1</i>	TGF- β receptor type I
<i>TGFBR2</i>	TGF- β receptor type II
<i>SMAD3</i>	Smad3
<i>SMAD2</i>	Smad2
<i>TGFB2</i>	TGF- β 2
<i>TGFB3</i>	TGF- β 3

SMC Contraction



<i>ACTA2</i>	smooth muscle α -actin
<i>MYH11</i>	smooth muscle myosin heavy chain
<i>MYLK</i>	myosin light chain kinase
<i>PRKG1</i>	cGMP-dependent kinase I
<i>ARIH1</i>	Ariadne-1 ubiquitin ligase

Channels


<i>MAT2A</i>	methionine adenosyltransferases II α
<i>FOXE3</i>	forkhead transcript factor E3
<i>HCN4</i>	Hyperpolarization-activated cyclic nucleotide-gated channel 4
<i>KCN5A</i>	Kv1.5 potassium channel

Cumulative Risk for an Aortic Event Based on HTAD Gene


Aortic Event = Surgical repair of an aneurysm, type A, or B dissection



Gene-Level Differences in Disease Severity





Variant-Level Differences in Disease Severity



Regalado et al. *J Am Coll Card* 2022 (MAC)

LDS Genes: Time to Arterial Event

Aneurysm repair, dissection or rupture



Personalized Management of Heritable Thoracic Aortic Disease: Montalcino Aortic Consortium

Dianna M. Milewicz, M.D. Ph.D.

President George H.W. Bush Chair


Director, John Ritter Research Program

McGovern Medical School

University of Texas Health Science Center at Houston




CENTRAL ILLUSTRATION Gene-Specific Thoracic Aortic Risk Models From the Montalcino Aortic Consortium



Data were collected from probands and family members with rare variants in seven genes predisposing to heritable thoracic aortic disease. Using these data, risk and type of first aortic event were stratified based on both the altered gene and recurrent variants within the genes.

Regalado ES, et al. *J Am Coll Cardiol*. 2022;80(9):857-869.

Prophylactic Root Replacement in Patients With High-Risk Clinical Features and Virulent Gene Variants




Regalado et al. *J Am Coll Card* 2022 (MAC)

<https://www.aats.org/resources/gene-guided-management-of-aortic-disease>

Prophylactic Root Replacement in Patients With High-Risk Clinical Features and Virulent Gene Variants

- 17-year-old woman with *PRKG1* variant and **normal root diameter**
- Father and two brothers died of acute type A dissections (ages 18-35 years)
- Underwent successful elective valve-sparing root replacement
 - Thin aortic wall
 - Smaller sutures (5-0)



Courtesy of Dr. Dianna Milewicz (UT Houston)
Photo used with patient permission

<https://www.aats.org/resources/gene-guided-management-of-aortic-disease>

Prophylactic Root Replacement in Patients With High-Risk Clinical Features and Virulent Gene Variants

- 47-year-old woman with *PRKG1* variant and 3.7 cm root
- Brother with acute dissection (age 35 years)
- Niece with acute dissection (fatal, age 16 years)
- Successful valve-sparing root replacement
- Thin aortic wall (1 mm) → technical modifications for cannulation, etc.



Preoperative


Postoperative

Norton et al. *J Thorac Cardiovasc Surg* 2019 (U Michigan)

<https://www.aats.org/resources/gene-guided-management-of-aortic-disease>

Personalised External Aortic Root Support (PEARS)


The new approach to surgical management of the dilated aorta



Personalised External Aortic Root Support (PEARS) is now emerging as an effective pre-emptive operation to halt aortic root expansion and maintain aortic valve function in Marfan syndrome and is also applicable in treating aortic root dilatation to prevent aneurysms associated with other aetiologies¹.


Image size: 164 x 256
View size: 1151 x 828
X: 0 px Y: 0 px Value: 0
WL: 310 WW: 722

CLINICAL_HEART_RBH RBH CMR 280905
1
12
TR: 2243.5, TE: 74.0
tse_17_db_t2_cb1 sag



Im: 1/1
Zoom: 323% Angle: 0
Thickness: 6.0 mm Location: -54.5

12:33:33
14/10/2005
Made with OsiriX



Patient 1: April 2004 (3 weeks pre-op) and January 2019 (15 years post-op)

PEARS Intention to Treat (NOV 2022)

Surgical conversions

Of 638 patients intended for Aortic PEARs surgery,

621 have been implanted,

5 were converted to VSRR,

1 converted to a Florida Sleeve,

4 converted to TRR,

3 converted to bio-Bentall,

2 converted to an inter position graft,

1 converted to MV replacement only.

97.33 surgical success

Mortality

1 patient died perioperatively

1 patient died 43 days post op

1 patient died 7 months after surgery.

0.47 CV mortality

- The patient who died perioperatively (number 36) had a severe pectus excavatus
- Patient number 530 died 43 days post-operatively after a successful surgery suffering a myocardial ischaemic event a few days post op resulting in myocardial stunning. This was managed with ECMO but the patient contracted an infection and died.
- Patient number 115 died 7 months after surgery. This patient had a history of aortic valve replacement and alcoholic cardiomyopathy that had been managed by implanting an ICD. This patient had a non-flow limiting lesion in their left circumflex artery prior to surgery. Postoperatively the patient developed cardiac failure due to an occluded circumflex coronary artery, which was managed by reoperation to adjust the ExoVasc support and application of a vein graft to the circumflex artery. Twelve days later the patient had a cardiac arrest and his ICD was reactivated. The patient died 6.5 months later of congestive heart failure.

Personalized External Aortic Root Support (PEARS) Jan 2023

2. Disease types treated


PEARS surgery has been applied to aortic management associated with the following established conditions:

- Marfan syndrome – 312 (20 patients having concurrent mitral repair)
- Loeys-Dietz syndrome - 39 (1 patient having concurrent mitral repair)
- Bicuspid Aortic Valve disease – 93 (1 patient having concurrent mitral repair)
- Idiopathic aortic dilation/other – 115 (inc. Turner's Syndrome, SMAD3, MYBCP3, NOS & FAAP)
- ACTA2 mutation – 3
- Ehlers Danlos Syndrome - 1
- Tetralogy of Fallot -1
- Transposition of the great arteries repaired by an arterial switch operation - 7
- Post free-standing root Ross op. autograft dilation – 11 (1 patient having concurrent MV repair)
- Aortic valve disease treated by the Ross Procedure – 96 (1 patient having concurrent mitral repair)
- Case Report Form yet to be received – 66

2022
and beyond...

Personalized Precision Medicine Approach

Refined based on clinical scenario, gene, and gene variant



*VEDS=Vascular Ehlers Danlos Syndrome
*FTAA= fortuitus thoracic aortic aneurysm

<https://www.aats.org/resources/gene-guided-management-of-aortic-disease>

Summary

- Diameter thresholds for aortic repair have evolved substantially
Dichotomy → Disease-Based → Gene-Based → Mutation-Based
- Genetic variants currently inform decisions about when to operate and how to operate
- Entering a new era of a precision medicine approach to data-driven, individualized care
- Decision making will be supported by integrated multidimensional patient-specific data: clinical features, imaging, genetics

[Home](#) >

[Digital Education & Resource Center](#) >

Gene-Guided Management of Aortic Disease

RESOURCE TYPE:

GLOBAL GRAND ROUNDS WEBINARS

GENE-GUIDED MANAGEMENT OF AORTIC DISEASE

November 2, 2022

Presented by:


Puja Kachroo, John Elefteriades,
Dianna Milewicz, Scott LeMaire,
Siddharth Prakash

Source:

AATS Webinars: Global Grand
Rounds

<https://www.aats.org/resources/gene-guided-management-of-aortic-disease>

FIGURE 17 Evaluation and Genetic Testing Protocol for Patients With TAD





CONGRESSO
SOCERGS
2 · 0 · 2 · 3

UNIÃO, ATUALIZAÇÃO E NETWORKING

Simpósio
SGCCV/SOCERGS

INDICAÇÃO DE CIRURGIA DE AORTA BASEADA EM PAINEL GENÉTICO. A MEDICINA DE PRECISÃO NA CIRURGIA CARDIOVASCULAR ESTÁ CHEGANDO?

Renato A. K. Kalil

Professor Titular jubilado de Clínica Cirúrgica da UFCSPA

Membro Titular da Academia Sul-Rio-Grandense de Medicina


Coordenador do Núcleo de Cardiopatias Congênicas do Hospital Moinhos de Vento

Cirurgião Cardiovascular nos Hospitais Moinhos de Vento, Divina Providência e Instituto de Cardiologia






2005 - 2022



- High Risk Clinical Factors**
- Severe systemic features
 - Family history of aortic events (young age, small diameters)
 - Rapid expansion (> 0.5 cm per year)

Without clinical risk factors
With clinical risk factors

Gene-Level Differences in Disease Severity




Number at risk

ACTA2	306	231	127	31	4
MYLK	55	51	34	17	1
PRKG1	37	30	12	2	0

— ACTA2 — MYLK — PRKG1

Variant-Level Differences in Disease Severity



Regalado et al. *J Am Coll Card* 2022 (MAC)

Comparative Risks of Initial Aortic Events Associated With Genetic Thoracic Aortic Disease

Ellen S. Regalado, PhD,^a Shaine A. Morris, MD, MPH,^b Alan C. Braverman, MD,^c Ellen M. Hostetler, BA,^a Julie De Backer, MD, PhD,^{d,e} Ruosha Li, PhD,^f Reed E. Pyeritz, MD, PhD,^g Anji T. Yetman, MD,^h Elena Cervi, MD,ⁱ Sherene Shalhub, MD,^j Richmond Jeremy, MB, BS, PhD,^k Scott LeMaire, MD,^l Maral Ouzounian, MD, PhD,^m Arturo Evangelista, MD,^{n,o} Catherine Boileau, PhD,^{e,o} Guillaume Jondeau, MD, PhD,^{e,o} Dianna M. Milewicz, MD, PhD^q

J Am Coll Card 2022

- 1028 patients with rare mutations in seven HTAD genes:
 - 3 genes related to SMC function: *ACTA2*, *MYLK*, *PRKG1*
 - 4 genes related to TGF-β signaling: *TGFBR1*, *TGFBR2*, *SMAD3*, *TGFB2*
- Sites: Australia, Belgium, Canada, Japan, France, Spain, UK, USA
- Cumulative probability of first aortic event: elective aneurysm repair or any aortic dis